Denali Therap (DNLI.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec4

Denali Therapeutics and Royalty Pharma Reach $275 Million Financing Agreement

12:02

H.C. Wainwright Analyst Maintains Buy Rating on Denali Therapeutics with Price Target

08:02

Nov17

Stifel Nicolaus Analyst Maintains Denali Therapeutics Buy Rating

12:22

Nov11

BTIG Analyst Reiterates Buy Rating on Denali Stock

11:56

Nov10

Oppenheimer Analyst Reiterates Buy Rating for Denali Therapeutics

14:23

Nov7

Denali Therap released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 0 (forecast USD 1.071 M), actual EPS USD -0.7359 (forecast USD -0.7471)

04:00

Schedules & Filings

Schedules

Filings

Nov6

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -126.9 M, EPS -0.7359

Aug11

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -124.12 M, EPS -0.7239

May6

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -132.97 M, EPS -0.7765

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change